Description

Monomethyl fumarate-d5 is deuterium labeled Monomethyl fumarate. Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[1][2][3].–Applications-COVID-19-immunoregulation-Formula-C5HD5O4-Citation–References-[1]Jiang D, et al. Monomethyl Fumarate Protects the Retina From Light-Induced Retinopathy. Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1275-1285.|[2]Sghaier R, et al. Dimethyl fumarate and monomethyl fumarate attenuate oxidative stress and mitochondrialalterations leading to oxiapoptophagy in 158N murine oligodendrocytes treated with 7β-hydroxycholesterol. J Steroid Biochem Mol Biol. 2019 Nov;194:105432.|[3]Tang H, et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008 Oct 31;375(4):562-5.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.-CASNumber-1616345-45-9-MolecularWeight-135.13-Compound Purity–SMILES-OC(/C([2H])=C([2H])/C(OC([2H])([2H])[2H])=O)=O-Research_Area-Inflammation/Immunology; Neurological Disease-Solubility-10 mM in DMSO-Target-Drug Metabolite;GPR109A;Isotope-Labeled Compounds-Isoform–Pathway-GPCR/G Protein;Metabolic Enzyme/Protease;Others-MCE Product type-Isotope-Labeled Compounds